PL3129374T3 - (5,6-Dihydro)pirymido[4,5-e]indolizyny - Google Patents

(5,6-Dihydro)pirymido[4,5-e]indolizyny

Info

Publication number
PL3129374T3
PL3129374T3 PL15712912T PL15712912T PL3129374T3 PL 3129374 T3 PL3129374 T3 PL 3129374T3 PL 15712912 T PL15712912 T PL 15712912T PL 15712912 T PL15712912 T PL 15712912T PL 3129374 T3 PL3129374 T3 PL 3129374T3
Authority
PL
Poland
Prior art keywords
indolizines
pyrimido
dihydro
Prior art date
Application number
PL15712912T
Other languages
English (en)
Inventor
Adrianus Petrus Antonius De Man
Rogier Christian Buijsman
Jan Gerard STERRENBURG
Joost Cornelis Marinus UITDEHAAG
Joeri Johannes Petrus DE WIT
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Research Center B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Research Center B.V. filed Critical Netherlands Translational Research Center B.V.
Publication of PL3129374T3 publication Critical patent/PL3129374T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15712912T 2014-04-07 2015-03-30 (5,6-Dihydro)pirymido[4,5-e]indolizyny PL3129374T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines
EP15712912.3A EP3129374B1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (1)

Publication Number Publication Date
PL3129374T3 true PL3129374T3 (pl) 2019-07-31

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15712912T PL3129374T3 (pl) 2014-04-07 2015-03-30 (5,6-Dihydro)pirymido[4,5-e]indolizyny

Country Status (16)

Country Link
US (3) USRE48974E1 (pl)
EP (1) EP3129374B1 (pl)
JP (1) JP6518690B2 (pl)
KR (1) KR102432420B1 (pl)
CN (1) CN106132963B (pl)
AU (1) AU2015243694B2 (pl)
BR (1) BR112016022342B1 (pl)
CA (1) CA2944610C (pl)
DK (1) DK3129374T3 (pl)
ES (1) ES2716165T3 (pl)
HU (1) HUE043108T2 (pl)
MX (1) MX368767B (pl)
PL (1) PL3129374T3 (pl)
PT (1) PT3129374T (pl)
RU (1) RU2692479C2 (pl)
WO (1) WO2015155042A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368767B (es) * 2014-04-07 2019-10-15 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e]indolizinas.
JP6993233B2 (ja) * 2015-04-17 2022-01-13 ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー
PL3416964T3 (pl) * 2016-02-19 2021-10-18 Phoenix Molecular Designs Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
US20250049926A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical compositions comprising modified betacyclodextrins
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
KR20240107329A (ko) * 2021-12-15 2024-07-09 신라젠(주) 신생물성 질환을 치료하는 방법
KR20240144991A (ko) * 2022-03-04 2024-10-04 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
KR101084871B1 (ko) 2003-05-22 2011-11-21 네르비아노 메디칼 사이언시스 에스.알.엘. 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
ES2572360T3 (es) * 2008-06-26 2016-05-31 Servier Lab Pirazolo-quinazolinas como moduladores de la actividad de la proteína quinasa
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
ES2553114T3 (es) 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
RU2591191C2 (ru) 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
ES2657979T3 (es) 2013-06-24 2018-03-07 Merck Patent Gmbh Compuestos de imidazol como moduladores de FSHR y sus usos
MX368767B (es) * 2014-04-07 2019-10-15 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e]indolizinas.

Also Published As

Publication number Publication date
JP6518690B2 (ja) 2019-05-22
USRE50082E1 (en) 2024-08-20
JP2017510595A (ja) 2017-04-13
EP3129374A1 (en) 2017-02-15
US9856258B2 (en) 2018-01-02
BR112016022342A8 (pt) 2021-07-20
USRE48974E1 (en) 2022-03-15
CA2944610C (en) 2024-01-09
KR20170013866A (ko) 2017-02-07
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
AU2015243694B2 (en) 2019-01-17
EP3129374B1 (en) 2018-12-19
RU2016141405A3 (pl) 2018-10-02
CN106132963A (zh) 2016-11-16
ES2716165T3 (es) 2019-06-10
BR112016022342B1 (pt) 2022-10-04
MX2016012997A (es) 2016-12-07
RU2016141405A (ru) 2018-05-07
MX368767B (es) 2019-10-15
CN106132963B (zh) 2019-08-06
CA2944610A1 (en) 2015-10-15
KR102432420B1 (ko) 2022-08-17
DK3129374T3 (en) 2019-04-08
AU2015243694A1 (en) 2016-11-03
PT3129374T (pt) 2019-03-25
BR112016022342A2 (pt) 2017-08-15
HUE043108T2 (hu) 2019-07-29
RU2692479C2 (ru) 2019-06-25

Similar Documents

Publication Publication Date Title
PL3129374T3 (pl) (5,6-Dihydro)pirymido[4,5-e]indolizyny
IL259169A (en) Novel pyrazolo pyrimidine derivatives
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL250823A0 (en) A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
IL243092A0 (en) New triazolo[d–4,5]pyrimidine histories
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
ZA201804619B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP3272627A4 (en) Multi-purpose vehicle
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
PT3119782T (pt) Compostos de 2,7-diazaspiro[3.5]nonano
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
IL250350A0 (en) History of tetrahydropyrrolo[4,3–][d3,1]thiazine as a BACE inhibitor
EP3227292A4 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
GB2578973B (en) Pyrrolopyrimidines as antitumor agents
HK1240222A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one compounds
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่